NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
Fate Therapeutics
Fate Therapeutics
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Senlang Biotechnology Inc., Ltd.
Gilead Sciences
Chiltern Pesquisa Clinica Ltda